Recombinant canine alpha-l-fucosidase: expression, purification, and characterization

Treatment of canine fucosidosis by intracisternal enzyme infusion

The blood brain barrier is the major obstacle to treating lysosomal storage disorders of the central nervous system such as canine fucosidosis. This barrier was overcome by three, monthly injections of recombinant canine α-l-fucosidase enzyme were given intracisternally. In dogs treated from 8 weeks of age enzyme reached all areas of central nervous system as well as the cervical lymph node, bone marrow and liver. Brainstem and spinal cord samples from regions adjacent to the injection site had highest enzyme levels (39-73% of normal). Substantial enzyme activity (8.5-20% of normal controls) was found in the superficial brain compared to deeper regions (2.6-5.5% of normal). Treatment significantly reduced the fucosyl-linked oligosaccharide accumulation in most areas of CNS, liver and lymph node. In the surface and deep areas of lumbar spinal cord, oligosaccharide accumulation was corrected (79-80% reduction) to near normal levels (p<0.05). In the spinal meninges (thoracic and lumbar) enzyme activity (35-39% of normal control) and substrate reduction (58-63% affected vehicle treated samples) reached levels similar to those seen in phenotypically normal carriers (p<0.05).The procedure was safe and well-tolerated, treated (average 16%) dogs gained more weight (p<0.05) and there was no antibody formation or inflammatory reaction in plasma and CSF following treatments. The capacity of early ERT to modify progression of biochemical storage in fucosidosis is promising as this disease is currently only amenable to treatment by bone marrow transplantation which entails unacceptably high risks for many patients.

Alpha-L-fucosidases: exoglycosidases with unusual transglycosylation properties

Apha-LFucosidases (EC 3.2.1.51), the only members of the CAZy family GH-29, are widespread glycosidases involved in many biological processes including inflammation, metastasis, and the lysosomal storage disease fucosidosis. Despite their biological significance, information concerning the mechanism of alpha-Lfucosidases has only recently become available. In an attempt to obtain further data concerning their mechanism, we have investigated the hydrolytic and transglycosylation properties of a canine and a mollusk (Pecten maximus) alpha-Lfucosidase. Our results show that, despite the evolutionary distance between these two species, both enzymes have similar hydrolysis and transglycosylation properties. Surprisingly, we found that, starting from monosaccharides, these exoglycosidases were able to catalyze efficiently the synthesis of highly branched fuco-oligosaccharides as large as tetrasaccharides, a unique feature for a wild-type exoglycosidase. The structural analysis of the compounds formed revealed that the regioselectivity of alpha-Lfucosidases is strongly influenced by the structure of the acceptor. This leads us to propose an enzymatic approach for the preparative synthesis of fuco-oligosaccharides. This will not only allow the synthesis of biological determinants containing fucose but also of new fucose-containing oligosaccharides as alpha-glycosynthases appear to be difficult to obtain.

Glycosidase−Substrate Interactions Analysis by STD-NMR Spectroscopy: Study of α-l-Fucosidase

Saturation transfer difference-nuclear magnetic resonance (STD-NMR) is a recently developed method used to study the interaction between large proteins and small ligands. It has been successfully employed for various interactions including those between oligosaccharides or glycomimetics, and binding proteins such as lectins and antibodies. We have demonstrated that this method can be used to directly study the interaction between glycosidases and their substrates. We chose to study alpha-l-fucosidases, which, despite their wide distribution among living organisms and their biological significance, have not been studied with regard to their reaction mechanism. We were able for the first time to show direct evidences for the minimum structural requirements for a compound to interact with these enzymes. These findings will be useful for the design of new inhibitors and to optimize the synthetic properties (transglycosylation) of alpha-l-fucosidases.

Purification and characterization of recombinant human lysosomal alpha-mannosidase

Lysosomal alpha-mannosidase (EC 3.2.1.24) is required in the degradation of the asparagine-linked carbohydrates of glycoproteins. Deficiency of this enzyme leads to the lysosomal storage disorder alpha-mannosidosis. As an initial step toward enzyme replacement therapy for alpha-mannosidosis, the human lysosomal alpha-mannosidase cDNA was cloned into the pcDNA 3.1 vector and expressed in Chinese hamster ovary cells. Dimethyl sulfoxide (DMSO) added to the cell culture media to induce growth arrest led to a 4-fold increase in the enzyme production, with an average yield of 3.2 mg L(-1) day(-1). alpha-Mannosidase was secreted as an active homodimer of a 130-kDa precursor that was proteolyzed into two polypeptides of 55 and 72 kDa during the subsequent purification of the enzyme. N-terminal sequence analysis of the purified enzyme revealed that the proteolysis occurred close to a cleavage site previously identified in the intracellular form of lysosomal alpha-mannosidase. Generation of monoclonal antibodies against the recombinant enzyme made it possible to develop a single-step immunoaffinity purification procedure for alpha-mannosidase. The immunoaffinity-purified enzyme which mainly consisted of the 130-kDa precursor, displayed specific activity and kinetics similar to those of the processed form. Recombinant alpha-mannosidase was taken up by cultured alpha-mannosidosis fibroblasts and was trafficked to the lysosomes via the mannose 6-phosphate pathway where it reduced the amounts of stored mannose-containing oligosaccharides.